Menu

Mutated Flu May Dodge Vaccine Protection

About half of the H3N2 influenza samples tested in the United States encode altered antigens from the strain used to produce this year’s vaccine.

Dec 8, 2014
Molly Sharlach

A 3-D print of an influenza virus, showing the surface antigens hemagglutinin (blue) and neuraminidase (red)FLICKR, NIAID

While widespread vaccination is still the best defense against the influenza virus, the US Centers for Disease Control and Prevention (CDC) warned last week (December 4) that many of this year’s circulating strains are different from the ones used to formulate the annual flu vaccine.

So far this season, more than 90 percent of the reported flu cases in the US are of the H3N2 subtype, and 52 percent of the samples tested have mutations in antigen-encoding genes compared to the sample used to produce the annual vaccine.

“They’re different enough that we’re concerned that protection from vaccination against the drifted H3N2 viruses may be lower than we usually see,” CDC Director Thomas Frieden said. “These changes can signal that the immune response provided by vaccination won’t protect as well for these viruses,” he said, but added that the vaccine “may have some effectiveness against the drifted strain,” McClatchy DC reported.

According to a CDC statement, the flu vaccine was 37 percent effective in 2007-2008, when a drift variant also predominated; the overall effectiveness in the U.S. is usually between 50 and 55 percent.

The CDC is recommending that clinicians promptly prescribe antiviral medications to suspected influenza patients, even before a confirmed diagnosis. Early treatment is particularly important for those who are more vulnerable to the virus’s effects, including children under 2, adults over 65, and others with certain medical conditions.

“It’s too early to say for sure that this will be a severe flu season, but Americans should be prepared,” Frieden said in a statement. “We can save lives with a three-pronged effort to fight the flu: vaccination, prompt treatment for people at high risk of complications, and preventive health measures, such as staying home when you’re sick, to reduce flu spread.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!